The 2nd Latin America Congress on
Controversies to Consensus in Diabetes, Obesity and Hypertension (CODHy)
Rio de Janeiro, Brazil, March 22-25, 2012 |
|
 |
| Preliminary Scientific Program |
 |
|
|
Hall A |
|
|
9:00-9:10 |
Plenary Session 1
Diabetes, Cardiovascular Diseases and Cancer
Congress Co-Chairpersons Introduction
J. Davidson, USA and I. Raz, Israel |
|
|
Insulin resistance: A multifaceted disease responsible for ASCVD and cancer
R. A. DeFronzo, USA |
|
|
Diabetes, obesity and cancer
|
|
9:50-10:10 |
Diabetes therapy and cancer
P. Home, UK |
|
10:10-10:30 |
Overview of diabetes in Latin America
A. R. Chacra, Brazil |
|
|
Prevention and Early Therapy
Chairs: A. R. Chacra, Brazil
A. Golbert, Brazil |
|
11:00-11:15
11:15-11:30
11:30-11:45 |
Prediabetes therapy: Lifestyle vs. Drugs
Lifestyle: J. Tuomilehto, Finland
Drugs: R.A. DeFronzo, USA
Discussion |
|
11:45-12:00
12:00-12:15
12:15-12:30 |
First line therapy in T2D: Combination therapy vs. Monotherapy
Combination: P. Aschner, Colombia
Mono: A. Forti, Brazil
Discussion |
|
|
Session3
Utilization of Insulin Therapy by GPs
Chairs: E. Standl, Germany
D. Abouganem, Panama |
|
13:30-13:45
13:45-14:00 |
Are all sulfonylurea (Su) even?
Yes: L. Litwak, Argentina
No: R. Medina-Santillán, Mexico |
|
14:00-14:15
14:15-14:30 |
Starting insulin therapy by GP: BASAL vs. Premix
BASAL: F. Lavalle, Mexico
Premix: B. Itzhak, Israel |
|
14:30-14:45
14:45-15:00
15:00-15:15 |
Insulin intensification by GP
Yes: P. Pozzilli, Italy
No: C. Musso, Argentina
Discussion |
|
|
Session 4
The Voice of China
Chair: G. Ning, China |
|
15:45-15:50 |
Chair Introduction
G. Ning, China |
|
15:50-16:10 |
Treatment of Type 2 diabetes with traditional Chinese medicine
|
|
16:10-16:25 |
Relationship of Urinary Bisphenol A Concentration to Risk for Prevalent Type 2 Diabetes in Chinese Adults
Y. Bi, China |
|
16:25-16:40 |
The long-term effect of lifestyle interventions to prevent diabetes in the China Da Qing Diabetes Prevention Study: a 20-year follow-up study
G. Li, China |
|
16:40-16:55 |
Stratifying and tailoring HbA1c control targets for adults with Type 2 diabetes: Interpretation of the consensus proposed by the Chinese Society of Endocrinology
N. Tong, China |
|
16:55-17:00 |
Concluding remarks
G. Ning, China |
|
Hall B |
|
|
|
Hypertension Controversies
Chair: Y. Sharabi, Israel |
|
11:00-11:15
11:15-11:30
11:30-11:45 |
Should we change the target blood pressure in diabetic patients?
Yes: A. Ramirez, Argentina
No: G.C. Aylwin, Chile
Discussion |
|
11:45-12:00
12:00-12:15
12:15-12:30 |
Should we avoid antihypertensive drugs that increase glucose/ obesity?
Yes: G.D. Waisman, Argentina
No: R. Lyra, Brazil
Discussion |
|
|
Session 6
RAAS in Diabetes
Chair: G. Waisman, Argentina |
|
13:30-13:50 |
Is intracellular RAAS blockade a therapeutic target?
M. Gironacci, Argentina |
|
13:50-14:10 |
ACEs, ARBs or DRI: What is the best choice?
A. Ramirez, Argentina |
|
14:10-14:30
14:30-15:15 |
Is RAAS blockade indicated in every (T2D) patient
Y. Sharabi, Israel
Discussion
|
|
Oral Presentations |
|
14:30-14:40 |
Impact of soy consumption on hypertension in women: A case study
from a low-income rural community in South Africa
W. Oldewage-Theron, South Africa,A. Egal |
|
14:40-14:50 |
Who are indicated for a glucose tolerance test among hypertensive patients?
Y.K. Kim, South Korea, Y.S. Kim, M.K. Lee, M.Y. Rhee, E.J. Cho, B.J. Kwon,
K.C. Sung, M.S. Hyon |
|
14:50-15:15 |
Discussion |
|
|
Session 7
Meet the Professor: Metabolic Syndrome
Chairs: E. Gruber de Bustos, Venezuela
J. E. Paolo de Oliveira, Brazil |
|
15:45-16:05
|
Metabolic Syndrome: Do we need this definition?
|
|
16:05-16:25
|
Testosterone for the management of Metabolic Syndrome
F. Saad, Germany
|
|
16:25-16:40
16:49-16:55 |
Intolerance to statin/ target HDL
Yes: R. Lyra, Brazil
No: R. Eldor, Israel |
|
16:55-17:00 |
Discussion |
|
|
|
|
|
Session 8
Obesity
Chair: S. Klein, USA |
|
|
Current and future non-surgical weight loss therapy
S. Klein, USA |
|
|
Are there weight loss-independent effects of upper gastrointestinal tract diversion on diabetes?
R. Cohen, Brazil |
|
11:35-11:50
|
How good is sleeve gastrectomy?
C. Boza, Chile |
|
11:50-12:05
12:05-12:30 |
Bio Markers in diabetes and obesity
B. Wajchenberg, Brazil
Discussion |
|
|
Session 9
Insulin Resistance/Beta Cell Role in Diabetes Progression
Chairs: R. A. DeFronzo, USA
L. Zagury, Brazil |
|
13:30-13:55 |
Tools to assess insulin resistance and Beta Cell function
|
|
13:55-14:20 |
Beta function:Evaluation and clinical applications
J.J. Gagliardino, Argentina
|
|
14:20-14:45
14:45-15:15 |
Insulin secretion and Insulin resistance: A dynamic interaction
R.A. DeFronzo, USA
Discussion |
|
|
Session 10
New Insights to Neuropathy in T2D
Chair: R. Niecestro, USA |
|
15:45-16:00
16:00-16:10 |
Peripheral Neuropathy and small fibers: Diagnosis and therapeutic approach
|
|
16:10-16:25
16:25-16:35 |
CAN: A tool to assess the diagnosis by the diabetologist
|
|
16:35-16:50
16:50-17:00 |
The brain: New insights with diabetes, Alzheimer and depression
R. Moreira, Brazil
Discussion |
| 17:00-19:00 |
SGLT2 Inhibition and the ‘CODHy’ Controversies: Glycaemic Control and Beyond
Satellite Symposium sponsored by Bristol-Myers Squibb & AstraZeneca
This educational programme is accredited by the Royal College of Physicians of the United Kingdom for 2 credits |
|
|
|
|
WebStudio.co.il